PT3581650T - Mutante de polipéptido de fator ix, as suas utilizações e um método para a sua produção - Google Patents

Mutante de polipéptido de fator ix, as suas utilizações e um método para a sua produção

Info

Publication number
PT3581650T
PT3581650T PT191745173T PT19174517T PT3581650T PT 3581650 T PT3581650 T PT 3581650T PT 191745173 T PT191745173 T PT 191745173T PT 19174517 T PT19174517 T PT 19174517T PT 3581650 T PT3581650 T PT 3581650T
Authority
PT
Portugal
Prior art keywords
factor
production
polypeptide mutant
mutant
polypeptide
Prior art date
Application number
PT191745173T
Other languages
English (en)
Original Assignee
Uniqure Biopharma B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41397565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3581650(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from ITBO2008A000564A external-priority patent/IT1394177B1/it
Priority claimed from ITBO2009A000275A external-priority patent/IT1395980B1/it
Application filed by Uniqure Biopharma B V filed Critical Uniqure Biopharma B V
Publication of PT3581650T publication Critical patent/PT3581650T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT191745173T 2008-09-15 2009-09-15 Mutante de polipéptido de fator ix, as suas utilizações e um método para a sua produção PT3581650T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITBO2008A000564A IT1394177B1 (it) 2008-09-15 2008-09-15 Polipeptide fattore ix modificato, sue utilizzazioni e metodo per la sua produzione
ITBO2009A000275A IT1395980B1 (it) 2009-05-06 2009-05-06 Polipeptide fattore ix modificato, sue utilizzazioni e metodo per la sua produzione

Publications (1)

Publication Number Publication Date
PT3581650T true PT3581650T (pt) 2023-03-08

Family

ID=41397565

Family Applications (1)

Application Number Title Priority Date Filing Date
PT191745173T PT3581650T (pt) 2008-09-15 2009-09-15 Mutante de polipéptido de fator ix, as suas utilizações e um método para a sua produção

Country Status (17)

Country Link
US (11) US9249405B2 (pt)
EP (5) EP4219547A3 (pt)
CA (1) CA2737094C (pt)
CY (2) CY1125885T1 (pt)
DK (2) DK3581650T3 (pt)
ES (2) ES2940323T3 (pt)
FI (2) FI3581650T3 (pt)
FR (1) FR23C1028I1 (pt)
HK (1) HK1244507A1 (pt)
HR (2) HRP20230259T1 (pt)
HU (2) HUE061345T2 (pt)
LT (2) LT3581650T (pt)
PL (2) PL3581650T3 (pt)
PT (1) PT3581650T (pt)
SI (1) SI3581650T1 (pt)
TR (1) TR201813067T4 (pt)
WO (1) WO2010029178A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3581650T (pt) 2008-09-15 2023-03-08 Uniqure Biopharma B V Mutante de polipéptido de fator ix, as suas utilizações e um método para a sua produção
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
AU2013293573B2 (en) 2012-07-25 2016-10-27 Catalyst Biosciences, Inc. Modified Factor X polypeptides and uses thereof
SI2956477T1 (sl) 2013-02-15 2021-03-31 Bioverativ Therapeutics Inc. Optimiran gen dejavnika VIII
EP3160478A4 (en) 2014-06-30 2018-05-16 Bioverativ Therapeutics Inc. Optimized factor ix gene
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
IL309741A (en) 2015-06-23 2024-02-01 Childrens Hospital Philadelphia Modified factor IX, and preparations, methods and uses for gene transfer to cells, organs and tissues
HUE059941T2 (hu) 2016-02-01 2023-01-28 Bioverativ Therapeutics Inc Optimalizált VIII-as faktor gének
AU2017301600B2 (en) 2016-07-26 2022-08-04 Biomarin Pharmaceutical Inc. Novel adeno-associated virus capsid proteins
CN116355883A (zh) * 2016-10-14 2023-06-30 四川至善唯新生物科技有限公司 一种高活性凝血因子ix突变体、重组蛋白与融合蛋白的制备与应用
AR112057A1 (es) 2017-05-22 2019-09-18 Baxalta Inc Vectores virales que codifican variantes de fix recombinantes con mayor expresión para la terapia génica de hemofilia b
US11452749B2 (en) 2017-07-10 2022-09-27 Uniqure Ip B.V. Means and methods for AAV gene therapy in humans
US11491212B1 (en) 2017-09-27 2022-11-08 Catalyst Biosciences, Inc. Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B
JP2021522811A (ja) 2018-05-09 2021-09-02 ビオマリン プハルマセウトイカル インコーポレイテッド フェニルケトン尿症の治療方法
US20200069819A1 (en) 2018-05-14 2020-03-05 Biomarin Pharmaceutical Inc. Stable expression of aav vectors in juvenile subjects
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
AU2019323747A1 (en) * 2018-08-20 2021-03-04 Ucl Business Ltd Factor ix encoding nucleotides
WO2021154414A2 (en) 2020-01-29 2021-08-05 Catalyst Biosciences, Inc. Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides
EP4362971A1 (en) * 2021-07-01 2024-05-08 CSL Behring Lengnau AG Factor ix subcutaneous administration with enhanced safety

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US5583107A (en) 1990-09-04 1996-12-10 Cor Therapeutics, Inc. Agents affecting thrombosis and hemostasis
US5223408A (en) 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
GB9408717D0 (en) 1994-05-03 1994-06-22 Biotech & Biolog Scien Res DNA sequences
US6227618B1 (en) 1996-02-23 2001-05-08 Schukra Usa, Inc. Cable attachment for a lumbar support
DE59711957D1 (de) 1996-06-11 2004-10-28 Roche Diagnostics Gmbh Rekombinante blutgerinnungsproteasen
US6315995B1 (en) 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
DE69841459D1 (en) 1997-02-14 2010-03-11 American Nat Red Cross Expression des active human factor ix im brustdrüsengewebe transgener tiere
US6531298B2 (en) 1997-07-21 2003-03-11 The University Of North Carolina At Chapel Hill Factor IX antihemophilic factor with increased clotting activity
US6200560B1 (en) * 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US7109170B2 (en) 1999-06-16 2006-09-19 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
WO2001070763A1 (en) 2000-03-22 2001-09-27 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
AU2002226028A1 (en) 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
US20040133930A1 (en) 2002-03-11 2004-07-08 Cooper Julian D. Production of high levels of transgenic factor ix without gene rescue, and its therapeutic uses
WO2002096454A1 (en) 2001-05-31 2002-12-05 D. Collen Research Foundation Vzw Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
JP2005501547A (ja) 2001-09-04 2005-01-20 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 修飾された第ｉｘ因子
US7179617B2 (en) * 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US20040009151A1 (en) 2002-04-04 2004-01-15 Kay Mark A. Methods for delivering recombinant adeno-associated virus virions to the liver of a mammal
AU2003221733A1 (en) * 2002-04-17 2003-11-03 University Of Florida Research Foundation, Inc. Improved raav vectors
WO2004031733A2 (en) 2002-10-02 2004-04-15 Catalyst Biosciences Methods of generating and screenign for porteases with altered specificity
EP2277996B1 (en) * 2003-05-21 2014-09-03 Genzyme Corporation Methods for producing preparations of recombinant AAV virions substantially free of empty capsids
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
CN101006175A (zh) 2004-08-17 2007-07-25 Csl百灵有限公司 经修饰的维生素k依赖性多肽
DE502004008275D1 (de) 2004-08-19 2008-11-27 Gerd Baer Hubladebühne mit querverschiebbarem Verbindungsrohr
WO2006031226A1 (en) 2004-09-13 2006-03-23 Saint Louis University Region of factor ixa protease domain that interacts with factor viiia and methods therefor
DK2438931T3 (da) * 2004-09-22 2013-12-02 St Jude Childrens Res Hospital Forbedret ekspression af faktor ix i genterapivektorer
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
CN101124328A (zh) 2004-12-15 2008-02-13 北卡罗来纳查佩尔山大学 嵌合载体
EP1940457B1 (en) 2005-10-21 2012-12-12 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
WO2007059473A2 (en) * 2005-11-12 2007-05-24 Introgen Therapeutics, Inc. Methods for the production and purification of adenoviral vectors
SI1969127T2 (sl) 2005-12-21 2017-10-30 Cnj Holdings, Inc Metoda pridobivanja biološko aktivnih proteinov, odvisnih od vitamina K, z rekombinantnimi metodami
US7867484B2 (en) 2006-01-27 2011-01-11 University Of North Carolina At Chapel Hill Heparin and heparan sulfate binding chimeric vectors
WO2007101681A1 (en) * 2006-03-07 2007-09-13 Baxter International Inc Highly phosphorylated and sulfated recombinant factor ix
US20080003202A1 (en) 2006-03-28 2008-01-03 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
US7588772B2 (en) * 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
DK2009990T3 (en) * 2006-04-07 2017-01-09 Univ Texas METHODS AND COMPOSITIONS RELATED TO adenoassociated VIRUSFAGPARTIKLER
CA2653154A1 (en) 2006-05-24 2007-11-29 Novo Nordisk Health Care Ag Prolonged fix analogues and derivatives
US20070280906A1 (en) * 2006-06-03 2007-12-06 Ognjen Petras Method to generate mirrored adenoassociated viral vectors
EP2037892B1 (en) 2006-06-19 2015-03-18 Asklepios Biopharmaceutical, Inc. Modified factor viii and factor ix genes and vectors for gene therapy
EP2084274A2 (en) * 2006-06-19 2009-08-05 Nautilus Technology LLC Modified coagulation factor ix polypeptides and use thereof for treatment
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
EP2108045B1 (en) * 2007-02-01 2013-12-11 Baxter International Inc. Improved fix-mutant proteins for hemophilia b treatment
WO2008119815A1 (en) 2007-04-02 2008-10-09 Novo Nordisk A/S Subcutaneous administration of coagulation factor ix
US20100137211A1 (en) 2007-04-11 2010-06-03 Monahan Paul E Methods and compositions for intra-articular coagulation proteins
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
BRPI0705943A2 (pt) 2007-04-19 2008-12-09 Nautilus Biotech formulaÇÕes de dosagem oral de polipeptÍdeos resistentes À protease e usos das mesmas para tratamento
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
US20110154516A1 (en) 2007-10-15 2011-06-23 Stafford Darrel W Human factor ix variants with an extended half life
CN102065887A (zh) 2008-04-16 2011-05-18 拜耳医药保健有限公司 因子ix的定点修饰
CN102083856A (zh) * 2008-04-16 2011-06-01 拜耳医药保健有限公司 经修饰的因子ix多肽及其用途
EP2811017A2 (en) 2008-04-21 2014-12-10 Novo Nordisk Health Care AG Hyperglycosylated human coagulation factor IX
EP2149603A1 (en) 2008-07-28 2010-02-03 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
PT3581650T (pt) 2008-09-15 2023-03-08 Uniqure Biopharma B V Mutante de polipéptido de fator ix, as suas utilizações e um método para a sua produção
AU2010266065B2 (en) 2009-06-25 2016-01-14 The University Of North Carolina At Chapel Hill Chimeric Factor VII molecules
KR20120060209A (ko) 2009-07-31 2012-06-11 바이엘 헬스케어 엘엘씨 변형된 인자 ｉｘ 폴리펩티드 및 그의 용도
TWI595004B (zh) 2010-11-03 2017-08-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
US10398787B2 (en) 2012-10-26 2019-09-03 Vrije Universiteit Brussel Vectors for liver-directed gene therapy of hemophilia and methods and use thereof
EP2881463A1 (en) 2013-12-09 2015-06-10 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
EP3270944B1 (en) 2015-03-17 2019-10-23 Vrije Universiteit Brussel Optimized liver-specific expression systems for fviii and fix
IL309741A (en) 2015-06-23 2024-02-01 Childrens Hospital Philadelphia Modified factor IX, and preparations, methods and uses for gene transfer to cells, organs and tissues
UA126016C2 (uk) 2015-08-03 2022-08-03 Біовератів Терапеутікс Інк. Злитий білок фактора іх

Also Published As

Publication number Publication date
CA2737094C (en) 2018-02-20
EP3581650B1 (en) 2022-12-28
US20110244550A1 (en) 2011-10-06
PL2337849T3 (pl) 2018-11-30
HRP20181442T1 (hr) 2018-12-14
DK2337849T3 (en) 2018-10-01
CY1125885T1 (el) 2024-02-16
US20170355973A1 (en) 2017-12-14
US9249405B2 (en) 2016-02-02
EP3581650A2 (en) 2019-12-18
HRP20230259T1 (hr) 2023-04-28
ES2940323T3 (es) 2023-05-05
HUS2300024I1 (hu) 2023-08-28
FIC20230026I1 (fi) 2023-07-25
HK1244507A1 (zh) 2018-08-10
TR201813067T4 (tr) 2018-09-21
US20210238573A1 (en) 2021-08-05
EP2337849B1 (en) 2018-06-13
EP4219547A2 (en) 2023-08-02
FR23C1028I1 (fr) 2023-10-06
LTPA2023521I1 (pt) 2023-08-25
DK3581650T3 (da) 2023-03-13
EP4219547A3 (en) 2023-10-18
US20200231958A1 (en) 2020-07-23
EP3252157A1 (en) 2017-12-06
US10465180B2 (en) 2019-11-05
US20210214704A1 (en) 2021-07-15
HUE061345T2 (hu) 2023-06-28
FI3581650T3 (fi) 2023-03-23
LT3581650T (lt) 2023-05-10
US20180258413A1 (en) 2018-09-13
PL3581650T3 (pl) 2023-05-22
CY2023016I2 (el) 2024-02-16
US20200190498A1 (en) 2020-06-18
EP3581650A3 (en) 2020-03-25
EP2337849A1 (en) 2011-06-29
US9982248B2 (en) 2018-05-29
US20220002702A1 (en) 2022-01-06
ES2687038T3 (es) 2018-10-23
US20200199564A1 (en) 2020-06-25
EP4032979A1 (en) 2022-07-27
EP4032979B1 (en) 2024-05-01
CY2023016I1 (el) 2024-02-16
CA2737094A1 (en) 2010-03-18
CA2737094F (en) 2010-03-18
SI3581650T1 (sl) 2023-06-30
WO2010029178A1 (en) 2010-03-18
US20160122740A1 (en) 2016-05-05
US20220090042A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
HUS2300024I1 (hu) IX-es faktor polipeptid mutáns, alkalmazásai és eljárás elõállítására
EP2246415A4 (en) IMPROVED PROMOTER AND METHOD FOR PRODUCING L-LYSINE USING THE PROMOTER
ZA200908428B (en) Method for the production of a component, and component
PL2080736T3 (pl) Aerożele węglowe, sposób ich wytwarzania i ich zastosowanie
HK1159151A1 (en) Carbon black, method for the production thereof, and use thereof
IL204555A0 (en) (carboxylalkylene-phenyl) phenyl-oxalamides, method for the production thereof, and use of same as a medicatment
ZA201007720B (en) Production method
EP2130909A4 (en) METHOD OF PRODUCING TOOTH AND TOOTH PRODUCED BY THE METHOD
EP2295563A4 (en) B-AMYLASE, ENCODING GENE AND PROCESS FOR PRODUCING THE SAME
LT2236610T (lt) Patobulintas promotorius ir jo panaudojimas l-lizino gamybos būdui
IL233881A (en) Yeast genetically modified yeasts for squalene production, a genetically modified yeast yeast preparation and method for making them
EP2189476A4 (en) NOVEL POLYPEPTIDE AND MANUFACTURING METHOD THEREFOR
EP2256194A4 (en) FLOCCULATING YEAST AND METHOD FOR PRODUCING THE SAME
HK1140967A1 (en) Vesicle-containing composition, and method for production thereof
ZA200901945B (en) Hydrogen production method
EP2374776A4 (en) METHOD FOR MANUFACTURING CARBON MATERIAL, AND CARBON MATERIAL
EP2384388A4 (en) Configurations and methods for improved subsea production control
ZA201200528B (en) Novel alkoxyenones and enaminoketones and a method for the production thereof
HRP20150188T1 (en) Assembly and method for paper production
PL2288500T3 (pl) Laminat i sposób jego wytwarzania
EP2262894A4 (en) RECOMBINANT MICROORGANISM AND PROCESS FOR PRODUCTION OF L-LYSINE
EP2327789A4 (en) NEW COMPOUND SIGNAMYCIN, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF
EP2423319A4 (en) NOVEL AMYCOLAMYCIN COMPOUND, METHOD FOR PRODUCING THE SAME AND USE THEREOF
GB0822093D0 (en) Improved phospholid and method for its production
GB0615139D0 (en) Alternative membrane production method